

# Richard D Kim

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6438522/publications.pdf>

Version: 2024-02-01

74  
papers

1,648  
citations

331259

21  
h-index

315357

38  
g-index

74  
all docs

74  
docs citations

74  
times ranked

2704  
citing authors

#	ARTICLE	IF	CITATIONS
1	Metagenomics and chemotherapy-induced nausea: A roadmap for future research. <i>Cancer</i> , 2022, 128, 461-470.	2.0	9
2	Integrating a Disease-Focused Tumor Board as a Delivery-of-Care Model to Expedite Treatment Initiation for Patients With Liver Malignancies. <i>Annals of Surgical Oncology</i> , 2022, 29, 2371-2380.	0.7	4
3	Phase I Study of Lenvatinib and Capecitabine with External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma. <i>Oncologist</i> , 2022, 27, 621-e617.	1.9	2
4	<i>BRAF</i> Mutations Are Associated with Poor Survival Outcomes in Advanced-stage Mismatch Repair-deficient/Microsatellite High Colorectal Cancer. <i>Oncologist</i> , 2022, 27, 191-197.	1.9	11
5	FGFR4 inhibitors for the treatment of hepatocellular carcinoma: a synopsis of therapeutic potential. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 393-400.	1.9	4
6	A phase I/IIb study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer. <i>European Journal of Cancer</i> , 2022, 169, 93-102.	1.3	30
7	Human Epidermal Growth Factor Receptor 2 Targeting Approaches for Colorectal Cancer: Clinical Implications of Novel Treatments and Future Therapeutic Avenues. <i>JCO Oncology Practice</i> , 2022, 18, 545-554.	1.4	8
8	The Application of Circulating Tumor DNA in the Screening, Surveillance, and Treatment Monitoring of Colorectal Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 1845-1858.	0.7	5
9	Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers. <i>Cancer</i> , 2021, 127, 1293-1300.	2.0	19
10	Endoscopic and MRI response evaluation following neoadjuvant treatment for rectal cancer: a pictorial review with matched MRI, endoscopic, and pathologic examples. <i>Abdominal Radiology</i> , 2021, 46, 1783-1804.	1.0	5
11	Pretreatment CT and PET Radiomics Predicting Rectal Cancer Patients in Response to Neoadjuvant Chemoradiotherapy. <i>Reports of Practical Oncology and Radiotherapy</i> , 2021, 26, 29-34.	0.3	9
12	Investigational PARP inhibitors for the treatment of biliary tract cancer: spotlight on preclinical and clinical studies. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 451-461.	1.9	6
13	A phase I/II trial of ibrutinib in combination with pembrolizumab in patients with mismatch repair proficient metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2021, 124, 1803-1808.	2.9	20
14	Regorafenib, an investigational agent for the treatment of cholangiocarcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 333-341.	1.9	3
15	Targeted Therapy for Advanced or Metastatic Cholangiocarcinoma: Focus on the Clinical Potential of Infigratinib. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 5145-5160.	1.0	14
16	Partial Splenic Artery Embolization in 35 Cancer Patients: Results of a Single Institution Retrospective Study. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 584-591.	0.2	7
17	A Phase I Trial of Trametinib in Combination with Sorafenib in Patients with Advanced Hepatocellular Cancer. <i>Oncologist</i> , 2020, 25, e1893-e1899.	1.9	16
18	Prevention and treatment of FGFR inhibitor-associated toxicities. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 155, 103091.	2.0	35

#	ARTICLE	IF	CITATIONS
19	ASO Author Reflections: Clinical Utility of Circulating Tumor DNA Analysis in Colorectal Cancer: Current Status. <i>Annals of Surgical Oncology</i> , 2020, 27, 890-890.	0.7	1
20	CT-based radiomic features to predict pathological response in rectal cancer: A retrospective cohort study. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2020, 64, 444-449.	0.9	20
21	A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer. <i>Cancer</i> , 2020, 126, 3464-3470.	2.0	24
22	A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer. <i>JAMA Oncology</i> , 2020, 6, 888.	3.4	293
23	Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer. <i>European Journal of Cancer</i> , 2020, 130, 219-227.	1.3	24
24	Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3557-3564.	3.2	4
25	Phase Ib study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 564-564.	0.8	17
26	Personalized Medicine in Advanced Cholangiocarcinoma. <i>Oncology &amp; Hematology Review</i> , 2020, 16, 52.	0.2	1
27	Immunotherapy in Hepatocellular Carcinoma: Is There a Light at the End of the Tunnel?. <i>Cancers</i> , 2019, 11, 1078.	1.7	36
28	FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma. <i>Cancer Treatment Reviews</i> , 2019, 78, 1-7.	3.4	57
29	A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2499-2511.	1.1	14
30	First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. <i>Cancer Discovery</i> , 2019, 9, 1696-1707.	7.7	157
31	Prediction of chemotherapy-induced nausea and vomiting from patient-reported and genetic risk factors. <i>Supportive Care in Cancer</i> , 2018, 26, 2911-2918.	1.0	16
32	Single Institute Experience With Methylphenidate and American Ginseng in Cancer-Related Fatigue. <i>American Journal of Hospice and Palliative Medicine</i> , 2018, 35, 144-150.	0.8	13
33	Prognostic value of CD8CD45RO tumor infiltrating lymphocytes in patients with extrahepatic cholangiocarcinoma. <i>Oncotarget</i> , 2018, 9, 23366-23372.	0.8	29
34	Intrahepatic Cholangiocarcinoma Treated with Transarterial Yttrium-90 Glass Microsphere Radioembolization: Results of a Single Institution Retrospective Study. <i>Journal of Vascular and Interventional Radiology</i> , 2018, 29, 1101-1108.	0.2	70
35	Novel targeted treatment options for advanced cholangiocarcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 709-720.	1.9	42
36	Nivolumab as salvage treatment in a patient with HIV-related relapsed/refractory Hodgkin lymphoma and liver failure with encephalopathy. , 2017, 5, 49.		29

#	ARTICLE	IF	CITATIONS
37	Clinicopathologic and survival analysis of resected ampullary adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2016, 114, 170-175.	0.8	27
38	Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma. <i>Radiotherapy and Oncology</i> , 2016, 118, 382-386.	0.3	10
39	Investigational drugs for treating anal cancer and future perspectives. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 51-62.	1.9	0
40	Viral hepatitis associated hepatocellular carcinoma outcomes with Y-90 radioembolization.. <i>Journal of Clinical Oncology</i> , 2016, 34, 414-414.	0.8	1
41	Using the ALBI grade as a prognostic marker for radioembolization of hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 366-366.	0.8	0
42	An investigator sponsored phase Ia/Ib trial of selinexor in combination with irinotecan in patients with adenocarcinoma of stomach and distal esophagus.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS176-TPS176.	0.8	1
43	A phase II therapeutic, open label, multi-center clinical trial of NPC-1C, a chimeric monoclonal antibody (mAb), in adults with chemotherapy refractory metastatic colorectal cancer (mCRC), initial results.. <i>Journal of Clinical Oncology</i> , 2016, 34, 500-500.	0.8	3
44	Impact of sarcopenia evaluated using the total psoas area (TPA) in patients undergoing Y-90 radioembolization for hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 217-217.	0.8	1
45	Prognostic significance of pre-treatment neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in locally advanced esophageal cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 172-172.	0.8	0
46	A phase I trial with cohort expansion of BYL719 in combination with gemcitabine and nab-paclitaxel in locally advanced and metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS467-TPS467.	0.8	0
47	Does metabolic tumor volume predict tumor regression grade after neoadjuvant therapy for borderline resectable pancreatic cancer?. <i>Journal of Clinical Oncology</i> , 2016, 34, 214-214.	0.8	0
48	A phase Ia/Ib trial of trametinib in combination with sorafenib in patients with advanced hepatocellular cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS469-TPS469.	0.8	0
49	Multi-institutional phase II trial of single agent regorafenib in refractory advanced biliary cancers.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS468-TPS468.	0.8	0
50	A single institution experience of EGFR inhibitors in patients with advanced squamous cell anal carcinomas (SCAC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 623-623.	0.8	0
51	Second-Line Treatment of Advanced Gastric Cancer: Where Do We Stand?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1281-1292.	2.3	11
52	Locally Advanced Gastroesophageal Junction Tumor: A Treatment Dilemma. <i>Oncologist</i> , 2015, 20, 134-142.	1.9	4
53	Outcomes of Therasphere Radioembolization for Colorectal Metastases. <i>Clinical Colorectal Cancer</i> , 2015, 14, 146-153.	1.0	32
54	Phase I trial of combination of FOLFIRI and pasireotide, a somatostatin analogue, in advanced gastrointestinal malignancies. <i>Investigational New Drugs</i> , 2015, 33, 1093-1099.	1.2	6

#	ARTICLE	IF	CITATIONS
55	Phase I study of combination of pasireotide LAR+Âgemcitabine in locally advanced or metastatic pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 481-487.	1.1	11
56	Triciribine Phosphate Monohydrate, an AKT Inhibitor, Enhances Gemcitabine Activity in Pancreatic Cancer Cells. <i>Anticancer Research</i> , 2015, 35, 4599-604.	0.5	12
57	Carboplatin and Paclitaxel Treatment Is Effective in Advanced Anal Cancer. <i>Oncology</i> , 2014, 87, 125-132.	0.9	39
58	In Reply. <i>Oncologist</i> , 2014, 19, 431-431.	1.9	4
59	Predictive Biomarkers for Anti-Epidermal Growth Factor Receptor Therapy: BeyondKRAS Testing. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1433-1442.	2.3	6
60	Geographic differences in approach to advanced gastric cancer: Is there a standard approach?. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 88, 416-426.	2.0	39
61	Viral Vector Vaccines To Treat Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2013, 9, 398-405.	1.0	2
62	Adjuvant Treatment for Gastric Cancer: Chemotherapy Versus Radiation. <i>Oncologist</i> , 2013, 18, 1013-1021.	1.9	38
63	Adjuvant treatment of hepatocellular carcinoma after orthotopic liver transplantation: do we really need this?. <i>Clinical Transplantation</i> , 2013, 27, 169-177.	0.8	11
64	Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation. <i>Clinical Transplantation</i> , 2013, 27, 555-561.	0.8	46
65	Harnessing gemcitabine metabolism: a step towards personalized medicine for pancreatic cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2012, 4, 341-346.	1.4	30
66	BRCA and pancreatic cancer: selection of chemotherapy. <i>JOP: Journal of the Pancreas</i> , 2012, 13, 180-1.	1.5	6
67	Radiologic Complete Response with Sirolimus and Sorafenib in a Hepatocellular Carcinoma Patient who Relapsed After Orthotopic Liver Transplantation. <i>Journal of Gastrointestinal Cancer</i> , 2011, 42, 50-53.	0.6	28
68	Prognostic roles of human equilibrative transporter 1 ( <i>hENT1</i> ) and ribonucleoside reductase subunit M1 ( <i>RRM1</i> ) in resected pancreatic cancer. <i>Cancer</i> , 2011, 117, 3126-3134.	2.0	51
69	What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge. <i>Oncology</i> , 2011, 25, 283-91, 295.	0.4	6
70	Adjuvant treatment for ampullary cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011. <i>JOP: Journal of the Pancreas</i> , 2011, 12, 362-3.	1.5	3
71	A Single Institution Review of Adjuvant Therapy Outcomes for Resectable Pancreatic Adenocarcinoma: Outcome and Prognostic Indicators. <i>Journal of Gastrointestinal Surgery</i> , 2010, 14, 1159-1169.	0.9	20
72	Safety and Feasibility of Using Sorafenib in Recurrent Hepatocellular Carcinoma after Orthotopic Liver Transplantation. <i>Oncology</i> , 2010, 79, 62-66.	0.9	48

#	ARTICLE	IF	CITATIONS
73	Is there a role for second-line chemotherapy in advanced gastric cancer?. Lancet Oncology, The, 2009, 10, 903-912.	5.1	98
74	Treatment Approaches for Hepatocellular Carcinoma. Clinical Medicine Oncology, 2007, 1, 117955490700100.	0.2	0